Olema Pharmaceuticals (NASDAQ:OLMA) Insider Shawnte Mitchell Sells 25,000 Shares of Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) insider Shawnte Mitchell sold 25,000 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $24.25, for a total value of $606,250.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Shawnte Mitchell also recently made the following trade(s):

• On Tuesday, March 3rd, Shawnte Mitchell sold 15,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $23.01, for a total transaction of $345,150.00.

Olema Pharmaceuticals Stock Down 1.8%

NASDAQ OLMA traded down $0.40 during trading on Friday, reaching $22.16. 210,663 shares of the company’s stock traded hands, compared to its average volume of 1,273,840. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.03 and a quick ratio of 8.03. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -11.85 and a beta of 1.92. The company’s 50 day simple moving average is $25.25 and its two-hundred day simple moving average is $17.95. Olema Pharmaceuticals, Inc. has a 12-month low of $2.86 and a 12-month high of $36.26.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Piper Sandler assumed coverage on Olema Pharmaceuticals in a research report on Wednesday, January 7th. They issued an “overweight” rating and a $40.00 target price on the stock. Stifel Nicolaus began coverage on shares of Olema Pharmaceuticals in a research note on Wednesday, February 11th. They set a “buy” rating and a $48.00 target price on the stock. JPMorgan Chase & Co. upped their target price on Olema Pharmaceuticals from $29.00 to $32.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. Citigroup increased their price target on shares of Olema Pharmaceuticals from $21.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research note on Thursday, January 22nd. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $41.78.

Institutional Trading of Olema Pharmaceuticals

Institutional investors have recently modified their holdings of the business. AQR Capital Management LLC purchased a new position in Olema Pharmaceuticals in the 1st quarter valued at approximately $172,000. Goldman Sachs Group Inc. raised its holdings in shares of Olema Pharmaceuticals by 93.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 741,329 shares of the company’s stock worth $2,787,000 after purchasing an additional 358,412 shares during the period. Jane Street Group LLC lifted its stake in shares of Olema Pharmaceuticals by 216.8% during the first quarter. Jane Street Group LLC now owns 138,552 shares of the company’s stock worth $521,000 after purchasing an additional 94,815 shares in the last quarter. ProShare Advisors LLC boosted its position in Olema Pharmaceuticals by 21.1% in the 2nd quarter. ProShare Advisors LLC now owns 14,766 shares of the company’s stock valued at $63,000 after buying an additional 2,569 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Olema Pharmaceuticals by 22.4% during the 2nd quarter. Geode Capital Management LLC now owns 1,326,123 shares of the company’s stock valued at $5,650,000 after acquiring an additional 242,997 shares during the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.